Alzheimer’s Disease – The Past, the Present and the Future

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Science Journal of Clinical Medicine

• Publication date

  2017-02-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.11648/J.SJCM.20170601.11
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Alzheimer’s Disease Prevention

  2017cited by this paper
• 2016 Alzheimer's disease facts and figures

  2016cited by this paper
• History of Alzheimer's Disease

  2016cited by this paper
• PPARγ-coactivator-1α gene transfer reduces neuronal loss and amyloid-β generation by reducing β-secretase in an Alzheimer’s disease model

  2016cited by this paper
• Astrocytic and microglial nicotinic acetylcholine receptors: an overlooked issue in Alzheimer’s disease

  2016cited by this paper
• The Epidemiology and Impact of Dementia

  2015cited by this paper
• A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

  2015cited by this paper
• Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.

  2015cited by this paper
• Anti-Diabetes Drug Pioglitazone Ameliorates Synaptic Defects in AD Transgenic Mice by Inhibiting Cyclin-Dependent Kinase5 Activity

  2015cited by this paper
• The Epidemiology and Impact of Dementia: Current State and Future Trends. WHO Thematic Briefing

  2015cited by this paper
• The Alzheimer conundrum: Entanglements of dementia and aging

  2015influential reference
• Fyn inhibition rescues established memory and synapse loss in Alzheimer mice

  2015cited by this paper
• Epigenetic drug discovery for Alzheimer’s disease

  2014cited by this paper
• Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.

  2014cited by this paper
• Trichostatin A increases the levels of plasma gelsolin and amyloid beta-protein in a transgenic mouse model of Alzheimer's disease.

  2014cited by this paper
• Crtc1 Activates a Transcriptional Program Deregulated at Early Alzheimer's Disease-Related Stages

  2014cited by this paper
• Alzheimer's disease susceptibility variants in the MS4A6A gene are associated with altered levels of MS4A6A expression in blood.

  2014cited by this paper
• CR1 and the "vanishing amyloid" hypothesis of Alzheimer's disease.

  2013cited by this paper
• Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease.

  2013cited by this paper
• Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models.

  2013cited by this paper
• Betaine attenuates Alzheimer‐like pathological changes and memory deficits induced by homocysteine

  2013cited by this paper
• Posterior Cortical Atrophy: Review of the Recent Literature

  2013cited by this paper
• Microglia in Alzheimer's Disease: It's All About Context

  2012cited by this paper
• Early-Onset Familial Alzheimer Disease

  2012cited by this paper
• The outdoor air pollution and brain health workshop.

  2012cited by this paper
• Genetics and epigenetics of Alzheimer's disease

  2012cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• BIN1 (bridging integrator 1)

  2011cited by this paper
• Diet and Alzheimer’s disease risk factors or prevention: the current evidence

  2011cited by this paper
• The history of the cholinergic hypothesis.

  2011cited by this paper
• Treatment of Alzheimer disease.

  2011cited by this paper
• Structure and biochemical analysis of the heparin-induced E1 dimer of the amyloid precursor protein

  2010cited by this paper
• Perspectives in Alzheimer's disease

  2010cited by this paper
• A meta-analysis of cytokines in Alzheimer's disease.

  2010cited by this paper
• Looking at neurotransmitters in the microscope.

  2010cited by this paper
• Alzheimer disease.

  2010cited by this paper
• Air Pollution : Mechanisms of Neuroinflammation & CNS Disease

  2009cited by this paper
• Neurobiology of Alzheimer's disease

  2009cited by this paper
• Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau

  2008cited by this paper
• The effect of curcumin (turmeric) on Alzheimer's disease: An overview

  2008cited by this paper
• Pediatric Respiratory and Systemic Effects of Chronic Air Pollution Exposure: Nose, Lung, Heart, and Brain Pathology

  2007influential reference
• Tauopathies

  2007cited by this paper
• Cumulative Lead Exposure and Cognitive Performance Among Elderly Men

  2007cited by this paper
• Cumulative Lead Dose and Cognitive Function in Adults: A Review of Studies That Measured Both Blood Lead and Bone Lead

  2006cited by this paper
• P3–370: APOE genotype has no influence in platelet and erythrocyte oxidative state

  2006cited by this paper
• Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease.

  2006cited by this paper
• Lead (Pb) exposure and its effect on APP proteolysis and Aβ aggregation

  2005cited by this paper
• The Fetal Basis of Amyloidogenesis: Exposure to Lead and Latent Overexpression of Amyloid Precursor Protein and β-Amyloid in the Aging Brain

  2005cited by this paper
• Fyn Kinase Induces Synaptic and Cognitive Impairments in a Transgenic Mouse Model of Alzheimer's Disease

  2005cited by this paper
• The microglial "activation" continuum: from innate to adaptive responses

  2005cited by this paper
• Role of tau protein in both physiological and pathological conditions.

  2004cited by this paper
• Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease

  2004cited by this paper
• Molecular Genetics of Late‐Onset Alzheimer's Disease

  2004cited by this paper
• The X-ray structure of an antiparallel dimer of the human amyloid precursor protein E2 domain.

  2004cited by this paper
• PS1 activates PI3K thus inhibiting GSK‐3 activity and tau overphosphorylation: effects of FAD mutations

  2004cited by this paper
• Cholinergic plasticity in hippocampus of individuals with mild cognitive impairment: Correlation with Alzheimer's neuropathology

  2003cited by this paper
• Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory.

  2003cited by this paper
• Glutamine and glutamate—their central role in cell metabolism and function

  2003cited by this paper
• Phosphorylation of Tau Is Regulated by PKN*

  2001cited by this paper
• Neuropsychologic effects of long-term exposure to pesticides: results from the French Phytoner study.

  2001cited by this paper
• Tau protein isoforms, phosphorylation and role in neurodegenerative disorders.

  2000cited by this paper
• The decline in synapses and cholinergic activity is asynchronous in Alzheimer’s disease

  2000cited by this paper
• The cholinergic hypothesis of Alzheimer’s disease: a review of progress

  1999cited by this paper
• Cholinergic markers in elderly patients with early signs of Alzheimer disease.

  1999cited by this paper
• Strategies That Support Declining Cholinergic Neurotransmission in Alzheimer’s Disease Patients

  1999cited by this paper
• Impact of Pcbs On Thyroid Hormone Directed Brain Development

  1998cited by this paper
• Neurofibrillary Tangles and Alzheimer’s Disease

  1998cited by this paper
• Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

  1998cited by this paper
• The possible role of peroxynitrite in Alzheimer's disease: a simple hypothesis that could be tested more thoroughly.

  1997cited by this paper
• 4‐Hydroxynonenal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule‐associated protein tau

  1997cited by this paper
• [Presenilin-1 (S182) causative gene of early-onset familial Alzheimer's disease].

  1996cited by this paper
• Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease

  1994cited by this paper
• APOE is a major susceptibility gene for Alzheimer's disease.

  1994cited by this paper
• Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.

  1993cited by this paper
• Hydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer's disease brain tissues.

  1991cited by this paper
• Acute hepatitis after tetrahydroaminoacridine administration for Alzheimer's disease.

  1990cited by this paper
• Non‐Alzheimer‐type pattern of brain cholineacetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy

  1989cited by this paper
• Alzheimer’s Dementia

  1985cited by this paper
• The cholinergic hypothesis of geriatric memory dysfunction.

  1982cited by this paper
• Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies.

  1976cited by this paper

• Innovative sensors with selectivity enhancement by molecularly imprinted polymers for the concurrent quantification of donepezil and memantine

  2025cites this paper
• Research Progress of Chemical Synthesis Drugs and Biotechnology Drugs for Alzheimer’s Disease

  2024cites this paper
• Alzheimer Disease: Recent Updates on Apolipoprotein E and Gut Microbiome Mediation of Oxidative Stress, and Prospective Interventional Agents

  2022cites this paper
• Development of grape polyphenols as multi-targeting strategies for Alzheimer's disease.

  2021cites this paper
• Nutrition: Review on the Possible Treatment for Alzheimer's Disease.

  2018cites this paper